JP2010515882A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010515882A5 JP2010515882A5 JP2009544931A JP2009544931A JP2010515882A5 JP 2010515882 A5 JP2010515882 A5 JP 2010515882A5 JP 2009544931 A JP2009544931 A JP 2009544931A JP 2009544931 A JP2009544931 A JP 2009544931A JP 2010515882 A5 JP2010515882 A5 JP 2010515882A5
- Authority
- JP
- Japan
- Prior art keywords
- sleep
- disorder
- disorders
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 claims description 110
- 208000019116 sleep disease Diseases 0.000 claims description 106
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims description 97
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims description 97
- 150000001875 compounds Chemical class 0.000 claims description 90
- 230000001737 promoting effect Effects 0.000 claims description 81
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 75
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 57
- 208000020685 sleep-wake disease Diseases 0.000 claims description 50
- 208000012902 Nervous system disease Diseases 0.000 claims description 47
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 46
- 208000035475 disorder Diseases 0.000 claims description 46
- 206010062519 Poor quality sleep Diseases 0.000 claims description 44
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims description 43
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 43
- 208000032140 Sleepiness Diseases 0.000 claims description 31
- 206010041349 Somnolence Diseases 0.000 claims description 31
- 230000037321 sleepiness Effects 0.000 claims description 31
- 230000000694 effects Effects 0.000 claims description 28
- 208000011580 syndromic disease Diseases 0.000 claims description 28
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims description 27
- 208000019695 Migraine disease Diseases 0.000 claims description 27
- 208000028017 Psychotic disease Diseases 0.000 claims description 26
- 239000005557 antagonist Substances 0.000 claims description 26
- 229940125425 inverse agonist Drugs 0.000 claims description 26
- 241000124008 Mammalia Species 0.000 claims description 25
- 210000004027 cell Anatomy 0.000 claims description 25
- 208000019901 Anxiety disease Diseases 0.000 claims description 22
- 206010010904 Convulsion Diseases 0.000 claims description 22
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 21
- 208000010877 cognitive disease Diseases 0.000 claims description 21
- 102000005962 receptors Human genes 0.000 claims description 19
- 108020003175 receptors Proteins 0.000 claims description 19
- 230000036461 convulsion Effects 0.000 claims description 17
- 206010022437 insomnia Diseases 0.000 claims description 16
- 206010027603 Migraine headaches Diseases 0.000 claims description 15
- 201000003631 narcolepsy Diseases 0.000 claims description 15
- 201000002859 sleep apnea Diseases 0.000 claims description 13
- 150000001413 amino acids Chemical class 0.000 claims description 12
- 206010027599 migraine Diseases 0.000 claims description 12
- 238000003752 polymerase chain reaction Methods 0.000 claims description 12
- 102000040430 polynucleotide Human genes 0.000 claims description 12
- 108091033319 polynucleotide Proteins 0.000 claims description 12
- 239000002157 polynucleotide Substances 0.000 claims description 12
- 238000012216 screening Methods 0.000 claims description 12
- 230000001773 anti-convulsant effect Effects 0.000 claims description 10
- 230000002460 anti-migrenic effect Effects 0.000 claims description 10
- 230000000561 anti-psychotic effect Effects 0.000 claims description 10
- 239000001961 anticonvulsive agent Substances 0.000 claims description 10
- 229960003965 antiepileptics Drugs 0.000 claims description 10
- 230000000949 anxiolytic effect Effects 0.000 claims description 10
- 208000003417 Central Sleep Apnea Diseases 0.000 claims description 9
- 208000028698 Cognitive impairment Diseases 0.000 claims description 9
- 206010012289 Dementia Diseases 0.000 claims description 9
- 208000001456 Jet Lag Syndrome Diseases 0.000 claims description 9
- 208000008705 Nocturnal Myoclonus Syndrome Diseases 0.000 claims description 9
- 208000005793 Restless legs syndrome Diseases 0.000 claims description 9
- 230000001430 anti-depressive effect Effects 0.000 claims description 9
- 239000000935 antidepressant agent Substances 0.000 claims description 9
- 229940005513 antidepressants Drugs 0.000 claims description 9
- 230000001419 dependent effect Effects 0.000 claims description 9
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 claims description 9
- 208000023515 periodic limb movement disease Diseases 0.000 claims description 9
- 231100000331 toxic Toxicity 0.000 claims description 9
- 230000002588 toxic effect Effects 0.000 claims description 9
- 239000012528 membrane Substances 0.000 claims description 8
- 208000025966 Neurological disease Diseases 0.000 claims description 6
- 238000007792 addition Methods 0.000 claims description 6
- 230000000295 complement effect Effects 0.000 claims description 6
- 238000012217 deletion Methods 0.000 claims description 6
- 230000037430 deletion Effects 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 239000012634 fragment Substances 0.000 claims description 6
- 239000003446 ligand Substances 0.000 claims description 6
- 238000006467 substitution reaction Methods 0.000 claims description 6
- 230000002194 synthesizing effect Effects 0.000 claims description 6
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 claims description 5
- 208000011688 Generalised anxiety disease Diseases 0.000 claims description 5
- 208000016588 Idiopathic hypersomnia Diseases 0.000 claims description 5
- 208000015814 Intrinsic Sleep disease Diseases 0.000 claims description 5
- 206010033664 Panic attack Diseases 0.000 claims description 5
- 208000014486 central sleep apnea syndrome Diseases 0.000 claims description 5
- 206010015037 epilepsy Diseases 0.000 claims description 5
- 208000029364 generalized anxiety disease Diseases 0.000 claims description 5
- 208000024714 major depressive disease Diseases 0.000 claims description 5
- 208000019906 panic disease Diseases 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 201000005439 recurrent hypersomnia Diseases 0.000 claims description 5
- 201000000980 schizophrenia Diseases 0.000 claims description 5
- 230000037410 cognitive enhancement Effects 0.000 claims description 4
- 239000008177 pharmaceutical agent Substances 0.000 claims description 4
- 210000004962 mammalian cell Anatomy 0.000 claims description 3
- 210000005253 yeast cell Anatomy 0.000 claims description 3
- 230000037007 arousal Effects 0.000 claims 6
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 230000000147 hypnotic effect Effects 0.000 claims 1
- 230000001788 irregular Effects 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 239000004031 partial agonist Substances 0.000 description 24
- 239000000556 agonist Substances 0.000 description 23
- 102100028628 Bombesin receptor subtype-3 Human genes 0.000 description 22
- 108010063504 bombesin receptor subtype 3 Proteins 0.000 description 22
- 239000008194 pharmaceutical composition Substances 0.000 description 20
- 239000003937 drug carrier Substances 0.000 description 8
- 208000033923 irregular sleep wake type circadian rhythm sleep disease Diseases 0.000 description 8
- 208000001797 obstructive sleep apnea Diseases 0.000 description 8
- 229940125724 sleeping drug Drugs 0.000 description 8
- 101000695054 Homo sapiens Bombesin receptor subtype-3 Proteins 0.000 description 4
- 230000037411 cognitive enhancing Effects 0.000 description 3
- 238000007596 consolidation process Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 2
- 229940126062 Compound A Drugs 0.000 description 1
- 229940080349 GPR agonist Drugs 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 210000003574 melanophore Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87879607P | 2007-01-05 | 2007-01-05 | |
| PCT/US2008/000116 WO2008085888A1 (en) | 2007-01-05 | 2008-01-04 | G protein-coupled receptor and modulators thereof for the treatment of gaba-related neurological disorders including sleep-related disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010515882A JP2010515882A (ja) | 2010-05-13 |
| JP2010515882A5 true JP2010515882A5 (enExample) | 2012-03-08 |
Family
ID=39472025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009544931A Withdrawn JP2010515882A (ja) | 2007-01-05 | 2008-01-04 | 睡眠関連障害を含むｇａｂａ関連神経学的障害を処置するためのｇタンパク質共役受容体およびその調節因子 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20110038850A1 (enExample) |
| EP (1) | EP2117577A1 (enExample) |
| JP (1) | JP2010515882A (enExample) |
| WO (1) | WO2008085888A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3131904A4 (en) * | 2014-04-15 | 2017-11-22 | Balance Therapeutics, Inc. | Methods for treating hypersomnia |
| AU2015270118C1 (en) | 2014-06-03 | 2019-11-28 | Idorsia Pharmaceuticals Ltd | Pyrazole compounds and their use as T-type calcium channel blockers |
| JP6500092B2 (ja) | 2014-09-15 | 2019-04-10 | イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ | Ｔ型カルシウムチャンネルブロッカーとしてのトリアゾール化合物 |
| TWI808952B (zh) | 2016-12-16 | 2023-07-21 | 瑞士商愛杜西亞製藥有限公司 | 包含t型鈣通道阻斷劑之醫藥組合 |
| CN110234622B (zh) | 2017-02-06 | 2023-07-04 | 爱杜西亚药品有限公司 | 用于合成1-芳基-1-三氟甲基环丙烷的新颖方法 |
| US11723579B2 (en) | 2017-09-19 | 2023-08-15 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement |
| US11717686B2 (en) | 2017-12-04 | 2023-08-08 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to facilitate learning and performance |
| US11478603B2 (en) | 2017-12-31 | 2022-10-25 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to enhance emotional response |
| US12280219B2 (en) | 2017-12-31 | 2025-04-22 | NeuroLight, Inc. | Method and apparatus for neuroenhancement to enhance emotional response |
| US11364361B2 (en) | 2018-04-20 | 2022-06-21 | Neuroenhancement Lab, LLC | System and method for inducing sleep by transplanting mental states |
| WO2020056418A1 (en) | 2018-09-14 | 2020-03-19 | Neuroenhancement Lab, LLC | System and method of improving sleep |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL149569A0 (en) * | 1999-11-17 | 2002-11-10 | Arena Pharm Inc | Endogenous and non-endogenous versions of human g protein-coupled receptors |
| WO2005011612A2 (en) * | 2003-07-31 | 2005-02-10 | The Research Foundation Of State University Of New York | Alpha 4 beta 2 delta gaba-a receptors as a strategy for pms and alcoholism |
| WO2005060625A2 (en) * | 2003-12-11 | 2005-07-07 | The Trustees Of Columbia University In The City Of New York | Grp receptor-related methods for treating and preventing fear-related disorders |
| GB0328796D0 (en) * | 2003-12-12 | 2004-01-14 | Biofocus Plc | Compounds which interact with the G-protein coupled receptor family |
| US8354241B2 (en) * | 2005-04-27 | 2013-01-15 | Arena Pharmaceuticals, Inc. | Methods for identifying a GLP-1 secretagogue |
-
2008
- 2008-01-04 US US12/521,274 patent/US20110038850A1/en not_active Abandoned
- 2008-01-04 EP EP08712989A patent/EP2117577A1/en not_active Withdrawn
- 2008-01-04 WO PCT/US2008/000116 patent/WO2008085888A1/en not_active Ceased
- 2008-01-04 JP JP2009544931A patent/JP2010515882A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010515882A5 (enExample) | ||
| JP6855466B2 (ja) | Ｌｓｄ１阻害剤に関連するバイオマーカーおよびそれらの使用 | |
| JP6012591B2 (ja) | β−ＮＧＦに対するアプタマー及びβ−ＮＧＦ介在疾患及び障害の治療におけるその使用 | |
| IL290294B2 (en) | Oligonucleotides for reduction of pd-l1 expression | |
| WO2017013061A1 (en) | Biomarkers associated with lsd1 inhibitors and uses thereof | |
| JP2009533024A5 (enExample) | ||
| JP2023053348A (ja) | 抗ｖｅｇｆで処置された加齢黄斑変性症に罹患している患者の臨床転帰に遺伝変異型を関連付ける方法 | |
| RU2012112802A (ru) | Диагностика интерферона типа 1 | |
| JP2013534908A5 (enExample) | ||
| JP2005505274A5 (enExample) | ||
| CN112961860A (zh) | 结合il-6的适体及其在治疗或诊断il-6介导的疾患中的用途 | |
| JP2018537093A (ja) | 異所性石灰化障害を治療するための組成物およびそれを使用する方法 | |
| WO2019133711A1 (en) | Methods of cancer treatment using an atr inhibitor | |
| JP2009526532A (ja) | Ｍｃｐ−１に結合する核酸 | |
| JP5822079B2 (ja) | 疼痛治療剤 | |
| CN105209438A (zh) | 苯氧基乙基二氢-1h-异喹啉化合物 | |
| CA3120534A1 (en) | Oligomeric nucleic acid molecule and use thereof | |
| KR20220082125A (ko) | 코로나 바이러스에 특이적으로 결합하는 dna 앱타머 및 이의 용도 | |
| JP4990513B2 (ja) | 睡眠障害マーカーおよび睡眠障害治療剤 | |
| CN1196784C (zh) | 人内皮特异受体基因的启动子及其用途 | |
| JP2007521333A5 (enExample) | ||
| EP3277835B1 (en) | Genetic predictors of a response to treatment with crhr1 antagonists | |
| CA2634488A1 (en) | Catecholamine regulated protein | |
| JP6103637B2 (ja) | 高病原性鳥インフルエンザウイルスの検出及びサーベイランス | |
| CN1176098C (zh) | 新的三螺旋形成寡核苷酸及其在抗乙肝病毒中的应用 |